Clinical, pathologic, and molecular features of amphicrine prostate cancer
Abstract
Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of prostate cancer in which cells co‐express luminal prostate epithelial and neuroendocrine markers. The optimal treatment strategy is unknown. We sought to further characterize the clinical, histomorphologic, and molecular characteristics of AMPC and to identify areas of potential future treatment investigations.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 13, 2023
- Source ID
- 10.1002/pros.24497
Entities
People
- Agnes Gawne
- Colin C Pritchard
- Erolcan Sayar
- Evan Y. Yu
- Ilsa M. Coleman
- Laura S Graham
- Michael C. Haffner
- Michael T Schweizer
- Peter S Nelson
Organizations
- Doris Duke Charitable Foundation
- Fred Hutchinson Cancer Center
- National Institutes of Health
- United States Department of Defense
- University of Colorado
- University of Washington